Similar articles for PMID: 36585206

Year	Number of Results
2007	1
2008	2
2009	2
2010	3
2011	3
2012	4
2013	7
2014	9
2015	16
2016	11
2017	4
2018	12
2019	14
2020	11
2021	11
2022	16
2023	5
2024	0

1

Clinical Verification on the Predictors for Febrile Neutropenia in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.

Goto W, Kashiwagi S, Matsuoka K, Iimori N, Kouhashi R, Yabumoto A, Takada K, Asano Y, Tauchi Y, Ogisawa K, Morisaki T, Shibutani M, Tanaka H, Maeda K. Goto W, et al. Anticancer Res. 2023 Jan;43(1):247-254. doi: 10.21873/anticanres.16156. Anticancer Res. 2023. PMID: 36585206

2

Prospective cohort study of febrile neutropenia in breast cancer patients administered with neoadjuvant and adjuvant chemotherapies: CSPOR-BC FN study.

Ishikawa T, Sakamaki K, Narui K, Nishimura H, Sangai T, Tamaki K, Hasegawa Y, Watanabe KI, Suganuma N, Michishita S, Sugae S, Aihara T, Tsugawa K, Kaise H, Taira N, Mukai H; for Comprehensive Support Project for Oncological Research of Breast Cancer. Ishikawa T, et al. Breast. 2021 Apr;56:70-77. doi: 10.1016/j.breast.2021.01.005. Epub 2021 Feb 16. Breast. 2021. PMID: 33631458 Free PMC article.

3

A retrospective analysis of nadir-neutropenia directed pegylated granulocyte-colony stimulating factor on febrile neutropenia rates in (neo)adjuvant breast cancer chemotherapy regimens.

Zardawi SJ, Nordman I, Zdenkowski N. Zardawi SJ, et al. Cancer Rep (Hoboken). 2020 Oct;3(5):e1266. doi: 10.1002/cnr2.1266. Epub 2020 Aug 6. Cancer Rep (Hoboken). 2020. PMID: 32761893 Free PMC article.

4

Impact of granulocyte-colony stimulating factor on docetaxel-induced febrile neutropenia in patients with breast cancer.

Zekri J, Nawaz A, Rasool H, Ahmad I, Abdel Rahman H, Dada R, Abdelghany EM, Farag K, Ibrahim RB, Deibas MY, Kamel MK, Allithy A. Zekri J, et al. J Oncol Pharm Pract. 2022 Dec;28(8):1681-1686. doi: 10.1177/10781552211030974. Epub 2021 Aug 3. J Oncol Pharm Pract. 2022. PMID: 34342555

5

Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.

Puértolas I, Frutos Pérez-Surio A, Alcácera MA, Andrés R, Salvador MDT. Puértolas I, et al. Eur J Clin Pharmacol. 2018 Mar;74(3):315-321. doi: 10.1007/s00228-017-2365-5. Epub 2017 Nov 19. Eur J Clin Pharmacol. 2018. PMID: 29152672 Clinical Trial.

6

Prophylactic administration of granulocyte colony-stimulating factor in epirubicin and cyclophosphamide chemotherapy for Japanese breast cancer patients: a retrospective study.

Sakurada T, Bando S, Zamami Y, Takechi K, Chuma M, Goda M, Kirino Y, Nakamura T, Teraoka K, Morimoto M, Tangoku A, Ishizawa K. Sakurada T, et al. Cancer Chemother Pharmacol. 2019 Nov;84(5):1107-1114. doi: 10.1007/s00280-019-03948-6. Epub 2019 Sep 9. Cancer Chemother Pharmacol. 2019. PMID: 31502114

7

Febrile neutropenia in adjuvant and neoadjuvant chemotherapy for breast cancer: a retrospective study in routine clinical practice from a single institution.

Bacrie J, Laurans M, Iorio P, Fourme E, Volters AB, Bozec L, Lerebours F, Dubot C, Bensaoula O, Benzidane B, Pierga JY, Lefeuvre D. Bacrie J, et al. Support Care Cancer. 2018 Dec;26(12):4097-4103. doi: 10.1007/s00520-018-4280-4. Epub 2018 May 31. Support Care Cancer. 2018. PMID: 29855772

8

Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.

Brito M, Esteves S, André R, Isidoro M, Moreira A. Brito M, et al. Support Care Cancer. 2016 Feb;24(2):597-603. doi: 10.1007/s00520-015-2818-2. Epub 2015 Jun 27. Support Care Cancer. 2016. PMID: 26111956

9

Febrile neutropenia and role of prophylactic granulocyte colony-stimulating factor in docetaxel and cyclophosphamide chemotherapy for breast cancer.

Kimura Y, Sasada S, Emi A, Masumoto N, Kadoya T, Okada M. Kimura Y, et al. Support Care Cancer. 2021 Jul;29(7):3507-3512. doi: 10.1007/s00520-020-05868-1. Epub 2020 Nov 4. Support Care Cancer. 2021. PMID: 33146835

10

Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancer.

Van Belle H, Hurvitz SA, Gilbar PJ, Wildiers H. Van Belle H, et al. Breast Cancer Res Treat. 2021 Dec;190(3):357-372. doi: 10.1007/s10549-021-06387-1. Epub 2021 Sep 17. Breast Cancer Res Treat. 2021. PMID: 34533681 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year